

Patient Journey for FLUMIST® (Influenza Vaccine Live, Intranasal)

Ordering, Shipping & At-Home Administration



1 Finding Out & Learning More About FLUMIST

FLUMIST
AstraZeneca website

Includes educational resources & support¹



[Flumist.com](https://www.flumist.com)



[Pharmacy partner website]

Third-party website that supports FLUMIST home service²

2 Ordering Through Online Pharmacy

Adult completes a digital form to **determine eligibility²**

3 Confirming Eligibility

Online pharmacist reviews the form, **confirms eligibility** and generates and fills prescription²

- Commercial insurance for the 2025/26 season**
Only private health insurance
- Age³**
2–49 years
- Medical eligibility²**
ACIP Recommendations

Pharmacist is available via chat or a **toll-free number** for questions,² as per Immunize.org **FLUMIST screening tool³**

4 Shipping & Delivery

Shipped under **conditions** to maintain appropriate temperature²

Patients will receive **tracking updates** and/or **delivery notifications** via text/email²



FLUMIST is delivered on the date selected by the patient²



5 Handling & Administration



Additional resources:²



INDICATION

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

IMPORTANT SAFETY INFORMATION

- Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
- When administered in a healthcare setting, appropriate medical treatment must be immediately available to manage potential anaphylactic reactions. When self-administered or administered by a caregiver, immediate medical attention should be sought if the vaccine recipient experiences symptoms of an allergic reaction

Please see additional Important Safety Information on next page and full [Prescribing Information](#), including [Patient Information](#) and [Instructions for Use](#).

Patient Journey for FLUMIST® (Influenza Vaccine Live, Intranasal)

Ordering, Shipping & At-Home Administration



6 Disposal of FLUMIST Sprayer & Packaging



After administration, the **single-use FLUMIST** sprayer(s) should be sent back using the **prepaid return envelope** included in the packaging²

Reporting Vaccination Status Through Immunization Information Systems (IIS)

Adult confirms administration of the vaccine. Pharmacy then reports vaccination to IIS.^{2,4,5}



Adult



[Pharmacy partner website]



Reporting service



Registries



CDC Dashboard

Documentation is available to patients and their health care providers^{2,a}

IMPORTANT SAFETY INFORMATION (continued)

- In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
- Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
- If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of potential benefits and risks
- The effectiveness of FLUMIST has not been studied in immunocompromised persons
- The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established
- FLUMIST may not protect all individuals receiving the vaccine
- The most common solicited adverse reactions (≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever >100 °F (children ages 2-6 years), and sore throat (adult ages 18-49 years)

INDICATION

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

You may report side effects related to AstraZeneca products  .
Please see full Prescribing Information, including Patient Information and Instructions for Use.

^aIf contact information provided.
ACIP = Advisory Committee on Immunization Practices; CDC = Centers for Disease Control and Prevention.
1. Coming as soon as next year: the only at-home flu vaccine, delivered with FluMist Home. FluMist website. Updated November 2024. Accessed February 26, 2025. <https://www.flumist.com/>; 2. In House Data, AstraZeneca. DoF 263898; 3. Screening checklist for contraindications to live attenuated intranasal influenza vaccination. Immunize.org. August 13, 2024. Accessed February 26, 2025. <https://www.immunize.org/wp-content/uploads/catg.d/p4067.pdf>; 4. Centers for Disease Control and Prevention. Immunization Information Systems Resources. May 17, 2024. Accessed February 26, 2025. https://www.cdc.gov/iis/about/index.html#cdc_data_surveillance; 5. Centers for Disease Control and Prevention. Influenza vaccine administration and coverage by jurisdiction, children and adults, United States. February 19, 2025. Accessed March 13, 2025. <https://www.cdc.gov/fluview/dashboard/vaccine-administration-coverage-jurisdiction-iis.html>.